Centrient Pharmaceuticals
Line Sandberg has an extensive work experience spanning various roles and companies in the pharmaceutical and manufacturing industries. Line currently holds the position of Chief Quality Officer at Centrient Pharmaceuticals since February 2023. Prior to that, they served as the Vice President Global Quality at Centrient Pharmaceuticals from April 2021 to February 2023.
Line also has board membership roles in Resino Trykfarver A/S starting from January 2017 and Cryos International from April 2018 to September 2021.
Line has had a long tenure with LEO Pharma A/S, where they held multiple positions including Vice President Global Quality and Continuous Improvement from October 2018 to April 2021, Vice President, Global Quality from May 2016 to October 2018, and Vice President Global Quality at LEO Pharma from May 2016 to April 2021.
Prior to their work at LEO Pharma, Line held various roles at Novozymes, including Vice President, Supply Operations from April 2013 to May 2016, Senior Director Supply Chain from May 2012 to April 2013, Senior Director - Supply Chain from August 2008 to March 2013, Global Quality Director from September 2005 to August 2008, and Senior Manager from August 2002 to September 2005.
Their early career started at Novo Nordisk, where Line worked as a Manager from April 1998 to August 2002, Project leader from February 1996 to April 1998, and Production Scientist from September 1992 to February 1996.
Throughout their career, Line has gained expertise in quality control, continuous improvement, supply chain management, and leadership roles.
Line Sandberg earned a B.Sc. degree in Biotechnology from DTU - Technical University of Denmark from 1988 to 1992. Line then pursued a B.Com. degree in Strategy, organization & management from Copenhagen Business School from 1992 to 1996. Additionally, Line Sandberg obtained certifications including "Educated Board Member" from BOARD GOVERNANCE A/S in 2012, and a "Lean Six Sigma Black Belt" from Hitachi Consulting (formerly Celerant Consulting) in 2005.
This person is not in any offices
Centrient Pharmaceuticals
2 followers
Centrient Pharmaceuticals is the global business-to-business leader in sustainable, enzymatic antibiotics, next generation statins and anti-fungals. We produce and sell intermediates and active pharmaceutical ingredients (APIs), as well as our own tablets, capsules and other finished dosage forms (FDFs). We stand proudly at the centre of modern healthcare, as a maker of essential and life-saving medicines. With our commitment to Quality, Reliability and Sustainability at the heart of everything we do, our over 1,800 employees work continuously to meet our customers’ needs. We work towards a sustainable future by actively participating in the fight against antimicrobial resistance. Founded 150 years ago as the ‘Nederlandsche Gist- en Spiritusfabriek’, our company was known as Gist Brocades and more recently DSM Sinochem Pharmaceuticals. Headquartered in Rotterdam (Netherlands), we have production facilities and sales offices in China, India, the Netherlands, Spain, the United States and Mexico. Centrient Pharmaceuticals is owned by Bain Capital Private Equity, a leading global private investment firm.